Press Releases


October 1, 2018
NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer

April 14, 2018
NGM Bio Announces Results From Phase 2 Study Of NGM282 In Nash Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks

April 13, 2018
NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis

March 12, 2018
NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018

February 5, 2018
NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)


October 19, 2017
NGM Bio Provides Update on NGM282 in NASH
Presents New NASH Data at The Liver Meeting 2017
Anticipates Results from 12-Week Histology Study in NASH Patients

October 2, 2017
Study Published in Nature Reveals Molecular Pathway of Weight-Controlling Hormone, Enabling the Discovery of Multiple Drug Candidates for Obesity and Cachexia

April 22, 2017
NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

April 5, 2017
NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017


June 8, 2016
NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH


November 9, 2015
NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD’s The Liver Meeting® 2015

September 30, 2015
NGM Bio is named one of FierceBiotech’s “Fierce 15” Biotech Companies of 2015

March 24, 2015
NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine

March 23, 2015
NGM Biopharmaceuticals Secures $57.5 Million Series D Financing

March 2, 2015
NGM Biopharmaceuticals Announces Expansion of Management Team 

February 23, 2015
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics 
Link to webcast: NGM and Merck Webcast


July 18, 2013
NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity

June 17, 2013
NGM Biopharmaceuticals and MedImmune, AstraZeneca’s Biologics Arm, Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity

January 3, 2013
NGM Enters Agreement With Janssen to Discover and Develop Novel Therapeutics for Diabetes


March 28, 2012
NGM and Daiichi Sankyo Collaborate to Discover and Develop Innovative Therapeutics for Diabetes


October 4, 2010
NGM Biopharmaceuticals Names William J. Rieflin Chief Executive Officer and Director

March 15, 2010
NGM Biopharmaceuticals Raises $51 Million in Series B Financing and Appoints New Board Member


October 21, 2009
NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, former Genentech CEO, to its Board of Directors 

September 1, 2009
NGM Biopharmaceuticals Appoints Helen S. Kim as Chief Business Officer 


February 11, 2008
NGM Biopharmaceuticals, Inc. Raises $25.5M